| 1. |
|
|
| 2. |
- Clementson, Martin, et al.
(författare)
-
Clinical and Patient-Reported Outcomes After Total Wrist Arthroplasty and Total Wrist Fusion : A Prospective Cohort Study with 2-Year Follow-up
- 2024
-
Ingår i: Journal of Bone and Joint Surgery. - 1535-1386. ; 9:1
-
Tidskriftsartikel (refereegranskat)abstract
- Background: The functional benefits of total wrist arthroplasty (TWA) over total wrist fusion (TWF) are unknown. The purpose of this prospective cohort study was to compare TWA and TWF with respect to functional outcomes and activitylimitations at up to 2 years postoperatively.Methods: Between 2015 and 2020, we enrolled all adult patients undergoing TWA or TWF for the management of symptomatic end-stage wrist arthritis at 1 hand surgery department. The primary outcome was the Patient-Rated Wrist Evaluation (PRWE). The secondary outcomes were the visual analog scale (VAS) for pain at rest, on motion, and on loading; grip strength; Disabilities of the Arm, Shoulder and Hand (DASH); and range of motion. Patients completed questionnairesand were examined by the same physiotherapist at baseline and at 3, 6, 12, and 24 months postoperatively. Mixed-model analyses adjusting for age, diagnosis, the preoperative value of the dependent variable, and time since surgery wereperformed to compare differences in PRWE scores, VAS pain scores, and grip strength between TWA and TWF.Results: Of the 51 patients who had been included at baseline, 47 (18 in the TWA group and 29 in the TWF group) responded to questionnaires and underwent examinations at up to 2 years postoperatively. At baseline, the 2 groups did not differ in terms of age, sex, diagnosis (inflammatory or noninflammatory arthritis), PRWE score, VAS pain score, grip strength, DASH score, or range of motion. No differences between the groups were found for the PRWE (b, 20.1; 95% confidence interval [CI], 214 to 13; p = 0.99), VAS pain at rest (b, 23.3; 95% CI, 215 to 9; p = 0.58), VAS pain on loading (b, 25.3; 95% CI, 222 to 11; p = 0.52), or grip strength (b, 20.02; 95% CI, 20.18 to 0.14; p = 0.80) on the adjusted mixed-model analyses.Conclusions: Among patients with symptomatic end-stage wrist arthritis, those who underwent TWA did not demonstrate short-term outcomes, including patient-reported disability, pain, and grip strength, superior to those of patients who underwent TWF. These findings call into question the widespread use of TWA.Level of Evidence: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.
|
|
| 3. |
- Kerremans, Art, et al.
(författare)
-
RESISTIRÉ D6.4: Overall report on Solutions
- 2023
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- This deliverable gives an overview of the different processes across all three cycles of the project that led to the development of RESISTIRÉ’s various outputs: the operational recommendations, the pilot projects, and the agendas for future research. The operational recommendations, designed as RESISTIRÉ factsheets, focused on 22 topics in total. For the pilot projects, seven different sets of terms of reference were developed over the first two cycles, eventually resulting in nine implemented pilot projects (two for Green Spaces as Ecosystems of Care and two for Engaging with Gender-based Violence Through Sports) across eight different countries. Finally, by the end of the third cycle, sixteen research agendas had been developed as well. Following the solutions created as part of the project, this report concludes with a section that indicates the various lessons that were learned throughout RESISTIRÉ’s three cycles. These lessons are differentiated by task, as the processes for developing the operational recommendations, pilot projects, and future research agendas all markedly differ from each other. They provide an insight into the strong points as well as the difficulties of the solution development processes.
|
|
| 4. |
|
|
| 5. |
- Strocov, V.N., et al.
(författare)
-
Momentum selectivity and anisotropy effects in the nitrogen K -edge resonant inelastic x-ray scattering from GaN
- 2005
-
Ingår i: Physical Review B. Condensed Matter and Materials Physics. - 1098-0121 .- 1550-235X. ; 72:8
-
Tidskriftsartikel (refereegranskat)abstract
- High-resolution soft x-ray emission and absorption spectra near the N K -edge of wurtzite GaN are presented. The experimental data are interpreted in terms of full-potential electronic structure calculations. The absorption spectra, compared with calculations including core hole screening, indicate partial core hole screening in the absorption process. The resonantly excited x-ray emission spectra show pronounced dispersion of spectral structures, which is attributed to effects of momentum conservation in the resonant inelastic x-ray scattering (RIXS) process. In development of GaN based optoelectronics, momentum selectivity in RIXS can be utilized to control development of band structure in GaN nanostructures. © 2005 The American Physical Society.
|
|
| 6. |
- Wang, Bei, et al.
(författare)
-
Softer, thinner and more complaint cochlear implants with liquid metal
- 2022
-
Konferensbidrag (refereegranskat)abstract
- A cochlear implant (CI) can restore sound perception for people with congenital or sensorineural hearing loss. Liquid metal (LM) based CI is more soft and complaint, enhancing its compliance and reducing intra-cochlear trauma, but the LM pattern demands high resolution. This work introduces a PCB manufacturing technique for high-resolution LM-based cochlear implant fabrication. It consists of laser cutting and ablation, masked LM microscale spray deposition, lift-off, and encapsulation. The microscale deposition is capable of patterning uniform LM at high resolution by fine spraying a sonication-produced LM particle based ink. A novel feature is that the laser-processable substrate is engraved when cutting the protective lift-off mask, avoiding mask transfer by lamination and allowing for alignment, vias, and higher aspect ratio structures, at high resolution. This feature simplifies the whole process and improves the precision and yield, allowing for more complex circuits. The fabricated CI shows good performance both in the inserting process and electrical signal.
|
|
| 7. |
- Carle, Fredrik, et al.
(författare)
-
Portable rescue device and a method for locating such a device
- 2007
-
Patent (populärvet., debatt m.m.)abstract
- A portable rescue device and a method for locating, by means of a first rescue device set in a search mode, a second rescue device set in a distress mode. In the method, a distress signal carrying a device identification is received from said second rescue device. A first bearing and a second bearing to the second rescue device are obtained. The first and second bearings are taken from a first and a second position, respectively. A distance between these positions is determined. A current distance and a current bearing to the second rescue device are determined on basis of the first and second bearings and the distance. The current bearing and the current distance are communicated to a user of the first rescue device. The portable rescue device is used for performing the method and for that purpose it includes a first communication unit for distress signal transmission and reception; a compass; a processor; a user interface; and a mode switch for switching between a search mode and a distress signal mode. The first communication device has an antenna structure that provides directional capability.
|
|
| 8. |
|
|
| 9. |
- Chaudhuri, K. Ray, et al.
(författare)
-
Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain : rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial
- 2022
-
Ingår i: BMC Neurology. - : Springer Science and Business Media LLC. - 1471-2377. ; 22:1
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Optimisation of dopaminergic therapy may alleviate fluctuation-related pain in Parkinson’s disease (PD). Opicapone (OPC) is a third-generation, once-daily catechol-O-methyltransferase inhibitor shown to be generally well tolerated and efficacious in reducing OFF-time in two pivotal trials in patients with PD and end-of-dose motor fluctuations. The OpiCapone Effect on motor fluctuations and pAiN (OCEAN) trial aims to investigate the efficacy of OPC 50 mg in PD patients with end-of-dose motor fluctuations and associated pain, when administered as adjunctive therapy to existing treatment with levodopa/dopa decarboxylase inhibitor (DDCi). Methods: OCEAN is a Phase IV, international, multicentre, randomised, double-blind, placebo-controlled, parallel-group, interventional trial in PD patients with end-of-dose motor fluctuations and associated pain. It consists of a 1-week screening period, 24-week double-blind treatment period and 2-week follow-up period. Eligible patients will be randomised 1:1 to OPC 50 mg or placebo once daily while continuing current treatment with levodopa/DDCi and other chronic, stable anti-PD and/or analgesic treatments. The primary efficacy endpoint is change from baseline in Domain 3 (fluctuation-related pain) of the King’s Parkinson’s disease Pain Scale (KPPS). The key secondary efficacy endpoint is change from baseline in Domain B (anxiety) of the Movement Disorder Society-sponsored Non-Motor rating Scale (MDS-NMS). Additional secondary efficacy assessments include other domains and total scores of the KPPS and MDS-NMS, the Parkinson’s Disease Questionnaire (PDQ-8), the MDS-sponsored Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Parts III and IV, Clinical and Patient’s Global Impressions of Change, and change in functional status via Hauser’s diary. Safety assessments include the incidence of treatment-emergent adverse events. The study will be conducted in approximately 140 patients from 50 clinical sites in Germany, Italy, Portugal, Spain and the United Kingdom. Recruitment started in February 2021 and the last patient is expected to complete the study by late 2022. Discussion: The OCEAN trial will help determine whether the use of adjunctive OPC 50 mg treatment can improve fluctuation-associated pain in PD patients with end-of-dose motor fluctuations. The robust design of OCEAN will address the current lack of reliable evidence for dopaminergic-based therapy in the treatment of PD-associated pain. Trial registration: EudraCT number 2020–001175-32; registered on 2020-08-07.
|
|
| 10. |
- Wang, Baoyuan, et al.
(författare)
-
Semiconductor-ionic Membrane of LaSrCoFe-oxide-doped Ceria Solid Oxide Fuel Cells
- 2017
-
Ingår i: Electrochimica Acta. - : Elsevier BV. - 0013-4686 .- 1873-3859. ; 248, s. 496-504
-
Tidskriftsartikel (refereegranskat)abstract
- A novel semiconductor-ionic La0.6Sr0.4Co0.2Fe0.8O3-delta (LSCF)-Sm/Ca co-doped CeO2 (SCDC) nanocomposite has been developed as a membrane, which is sandwiched between two layers of Ni0.8Co0.15Al0.05Li-oxide (NCAL) to construct semiconductor-ion membrane fuel cell (SIMFC). Such a device presented an open circuit voltage (OCV) above 1.0 V and maximum power density of 814 mW cm(-2) at 550 degrees C, which is much higher than 0.84 V and 300 mW cm(-2) for the fuel cell using the SCDC membrane. Moreover, the SIMFC has a relatively promising long-term stability, the voltage can maintain at 0.966 V for 60 hours without degradation during the fuel cells operation and the open-circuit voltage (OCV) can return to 1.06 V after long-term fuel cell operation. The introduction of LSCF electronic conductor into the membrane did not cause any short circuit but brought significant enhancement of fuel cell performances. The Schottky junction is proposed to prevent the internal electrons passing thus avoiding the device short circuiting problem.
|
|
